Optimal antiplatelet strategy after transcatheter aortic valve implantation: a meta-analysis. Issue 1 (26th January 2018)

• Record Type: Journal Article
• Authors: Ahmad, Yousif; Demir, Ozan; Rajkumar, Christopher; Howard, James P; Shun-Shin, Matthew; Cook, Christopher; Petraco, Ricardo; Jabbour, Richard; Arnold, Ahran; Frame, Angela; Sutaria, Nilesh; Ariff, Ben; Kanaganayagam, Gajen; Francis, Darrel; Mayet, Jamil; Mikhail, Ghada; Malik, Iqbal; Sen, Sayan
• Is Part Of: Open heart. Volume 5:Issue 1(2018)
• Publication Date: 2018-01-26
• Subjects: percutaneous valve therapy -- antiplatelet treatment -- aortic valve disease -- stroke; Cardiology -- Periodicals; Heart -- Diseases -- Periodicals; Heart -- Diseases -- Patients -- Periodicals; 616.12005
• DOI: 10.1136/openhrt-2017-000748
• Languages: English
• ISSNs: 2398-595X

Abstract

Abstract : Objective: International guidelines recommend the use of dual antiplatelet therapy (DAPT) after transcatheter aortic valve implantation (TAVI). The recommended duration of DAPT varies between guidelines. In this two-part study, we (1) performed a structured survey of 45 TAVI centres from around the world to determine if there is consensus among clinicians regarding antiplatelet therapy after TAVI; and then (2) performed a systematic review of all suitable studies (randomised controlled trials (RCTs) and registries) to determine if aspirin monotherapy can be used instead of DAPT. Methods: A structured electronic survey regarding antiplatelet use after TAVI was completed by 45 TAVI centres across Europe, Australasia and the USA. A systematic review of TAVI RCTs and registries was then performed comparing DAPT duration and incidence of stroke, bleeding and death. A variance weighted least squared metaregression was then performed to determine the relationship of antiplatelet therapy and adverse events. Results: 82.2% of centres routinely used DAPT after TAVI. Median duration was 3 months. 13.3% based their practice on guidelines. 11 781 patients (26 studies) were eligible for the metaregression. There was no benefit of DAPT over aspirin monotherapy for stroke (P=0.49), death (P=0.72) or bleeding (P=0.91). Discussion: Aspirin monotherapy appears to be as safe and effective as DAPT after TAVI.